Vasomedical WKN 882846 Rebounder?!

And in the investment world, according to Soros, when a investments positive perception becomes reality large sums are made by the few who realize it first. Longs & Strong  

davor noch grün?

immerhin ist hier endlich volatilität drin.

 

Vasomedical Announces Financial Results for the Second Quarter of 2013
Total revenues increased to $7.9 million
Company has repurchased approximately 8 million shares of its common stock through its share buyback program
PR NewswirePress Release: Vasomedical, Inc. – 10 minutes ago

   Email
   Print

RELATED QUOTES
    Symbol     Price    Change          §
      VASO      0.27 -0.01
§
WESTBURY, N.Y., Aug. 13, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO) today reported its operating results for the three months ended June 30, 2013.

"We are pleased by the continued growth reported for the second quarter of 2013, mostly attributable to the increased activity in our sales representation business in the U.S. and our operations in China," stated Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "We are encouraged by the success of our diversification and growth strategy, and look forward to seeing our efforts through to fruition in all aspects of our business."

"Looking ahead, we will continue to implement the Company's growth strategy by expanding the sales teams for each of our subsidiaries and looking to develop new services and product lines. These investments have already had an early impact on our results establishing a solid foundation from which to drive future growth. While it is still early in the process, we believe these investments will have a positive impact on a long-term basis."

"As previously announced, we initiated a share repurchase program in April, which we believe provides a strong vote of confidence to the investment community. As of July 30, 2013, we had acquired approximately 8 million shares of the Company's common stock. Our board of directors recently increased the buyback program by $500,000, for a total of $2 million. This program is part of our multi-pronged strategy to build shareholder value," concluded Dr. Ma.  

Three Months Ended June 30, 2013 Financial Results

For the three months ended June 30, 2013, revenue increased 3% to $7.9 million from $7.7 million for the three months ended June 30, 2012. This is primarily attributable to an increase in commission revenue recognized from our Sales Representation business in the second quarter of 2013, as a result of an increase in volume of equipment delivered by GEHC.

Gross profit for the second quarter of 2013 was $5.4 million, compared to a gross profit of $5.5 million for the second quarter of 2012.  The decrease is primarily due to a decrease in the sales representation segment margin, offset by an increase in equipment segment margin.  The equipment segment gross margin increased to 62.9% for the three months ended June 30, 2013 from 56.7% for the same period in 2012.  The decrease in the margin in the sales representation segment is due to the lower commission rate on GEHC orders received in 2012 and delivered in 2013.  We anticipate that these margins will improve in the second half of 2013 as we expect to achieve a higher commission rate on 2013 orders.  

Selling, general and administrative (SG&A) expenses for the second quarter of 2013 were $5.7 million compared to $5.3 million for the same period last year. The increase in SG&A expenditures in the second quarter of 2013 resulted primarily from increased costs associated with the expansion of the Equipment segment sales team of approximately $200,000, as well as $140,000 higher costs in the Sales Representation segment, of which $76,000 are non-recurring costs associated with the extension of our GEHC contract.

Net loss for the three months ended June 30, 2013 was $537,000, or $0.00 per basic and diluted common share, compared to net income of $54,000, or $0.00 per basic and diluted common share, for the three months ended June 30, 2012.

Cash flow from operations for the six months ended June 30, 2013 was $336,000.  We continue to maintain a strong financial position with a cash balance of $11.6 million at June 30, 2013.

Conference Call Information

The Company will host a conference call tomorrow, Wednesday, August 14th at 11:00 a.m. ET. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4996 internationally. All dial-in participants must use the following code to access the call: 26595138.  

die zahlen haben meine erwartungen zwar nicht erfüllt, aber die aussichten auf weitere nachrichten und zukünftige entwicklungen stimmen positiv! vaso ist beispielsweise in direktem contact mit versicherungsträgern.

neue studie von privatem träger für weitere anwendungsfelder der eecp therapie.

hoffnungen auf nachrichten im 2. halbjahr bezüglich verbesserter einschätzung durch krankenversicherungen wurden, auf nachfrage, erwähnt.

insgesamt sehr konservativ unser dr. jun ma, aber inhaltlich ein sehr guter cc.

 

that was by far the most positive information yet on CMS/Stonybrook that we have received. while nothing was specifically disclosed, it does appear we have a timeline (2H13) for a specific update and it appears there are several fronts they are working on CMS (directly, on Capitol Hill, and through Stonybrook).

i think they missed the intent/significance of EECP not being mentioned in the quarterly results. while it is a small part of the overall balance sheet right now - it is 90%+ of the expectations of WS/investors. that is the prize. that is where the "holy grail" is at. you do not have the share overhang to be a distributor or geometrically increase BIOX sales. it could be my background in technical sales but EVERY time you speak to customers you are selling. in this case - the PR is speaking to investors and they are trying to "sell" the company as an investment. unless it is specifically related to GEHC or BIOX, etc - every item should mention/address EECP and reinforce the leadership position in ECP therapy and that they are actively, aggressively working on expansion.

i was in the que for a question when we ran out of time on the insider purchase/open period. i wanted to get a comment on that even if it was vague. they addressed the buyback and added a little more information but not much. there seemed to be a certain amount of confidence in Ma's tone relative to the buyback. based on his comments on CMS, discussions with senators and Rios efforts right now, and the Stonybrook trial (that he referred to as a "major trial" - that would be sufficient noise to prevent an open window that would pass scrutiny with the SEC.

they still seem to be either overly conservative or somewhat disconnected between their PRs and their apparent confidence in the direction of the company. for those not deeply involved with the history and ongoings - that PR would not drive interest and the follow up CC would not have shed much more light or enthusiasm

PART 2

I am picking up on certain nuances, changes in tone from cc to cc to make objective assumptions on where that enthusiasm is internally. however, the general market will never get excited.

if the enthusiasm is real and we have a legitimate opportunity at incremental to groundbreaking changes with CMS by the end of the year - than this still should be agreat buying opportunity long term. however, from a trading standpoint, i think we will probably revert back to a "wait and see" approach from the market that does not share in our belief.

finally - going back to Stonybrook - i reread their PR on the new center and coupled with todays comments on the CC - the story has a lot more impact than when i originally read it. stonybrookmedicine.edu / newsroom / wellnesscenter (remove spaces).

$7.5MM for this center and its primary purpose (from the stonybrook PR) "The center will focus primarily on studying the noninvasive diagnosis and treatment of endothelial dysfunction – a condition in which the endothelium (inner lining) of blood vessels does not function normally, resulting in a myriad of vascular diseases – and on the effect of EECP in preventing the onset and progression of cerebral, coronary and peripheral vascular diseases. " and then further:

"Research being conducted at the center could ultimately benefit not only patients with or at risk of developing coronary artery disease, Dr. Poon said, but also heart failure and Alzheimer’s disease, which is primarily a vascular disorder, as the results are translated into new approaches to patient care. Hundreds of patients will benefit from receiving EECP as an FDA approved treatment during the course of research exploring alternative uses for the therapy. Additional exploratory research will examine the use of EECP in preventing muscle soreness and injury in elite athletes. "
PART 3
as far as duration of the trial/studies : "Through Dr. Poon’s research, patients will be assessed every three to six months over a three-year period to assess the effect of EECP on endothelial function. Their quality of life will be assessed and the cost-effectiveness of their care will be analyzed."

while the results will still be drawn out over time - one of the keys here is the study of cost-effectiveness of the care. while the 3rd parties have focused on efficacy - none that i have looked at have specifically looked at the cost of care as a major focus. this obviously is critical with CMS and 3rd party insurers.

i am definitely feeling better after the CC than before. however, the enthusiasm comes strictly from the Q&A and some subtle references. i dont think the market is going to feel the same.

i will see where trading shakes out the next couple of days. i expect the volume to be somewhat light. i may start buying again depending on where it ends up and what kind of activity we see on the SELL side. i doubt the MM will be scared off by the CC and will probably continue to aggressively short  

bei 0,3 ist das nächste resistance level  

man beachte, dass vasomedical diese klassifizierung in us anstrebt!!

EECP Therapy Receives Class lla Recommendation in European Society of Cardiology Guidelines for the Management of Stable Coronary Artery Disease

New Guidelines Recommended EECP Therapy as a Top Treatment Option for Refractory Angina in its First Inclusion

WESTBURY, N.Y., Sept. 9, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices for noninvasive cardiology including EECP^® (Enhanced External Counterpulsation) Therapy systems, the gold standard of ECP therapy, announced today that its EECP Therapy has been given a lla Class of Recommendation in the 2013 European Society of Cardiology (ESC) Guidelines on the Management of Stable Coronary Artery Disease (SCAD). The guidelines were released during ESC's annual meeting which took place from August 31 to September 3, 2013 in Amsterdam, the Netherlands. 

The IIa classification signifies that the weight of evidence and level of opinion are in favor of a treatment and, in this case, that physicians should consider EECP Therapy as a treatment option for patients suffering from refractory angina.

Last November, The American College of Cardiology Foundation and The American Heart Association (ACCF/AHA) Task Force on Practice Guidelines issued its new Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease. In this Guideline, EECP Therapy retained the same IIb Class of Recommendation rating it had received in the ACC/AHA 2002 Guideline Update for the Management of Patients with Chronic Stable Angina.  The Company has been in active communication with the ACCF/AHA task force, as well as its guideline writing committee, requesting a review of more recent data than was referenced in the 2012 Guideline, for the purpose of upgrading EECP Therapy's level of recommendation to lla in its future guideline.

"It is a breakthrough that EECP Therapy was included in the ESC Guidelines for the first time, and at the same time was given a level IIa recommendation, which means it 'should be considered' as a treatment option as opposed to 'may be considered' recommendation for a IIb rating," said Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "We are pleased that the European Society of Cardiology has recognized the value and efficacy of this treatment, as has been demonstrated by many studies. On behalf of all heart patients, we thank the many physicians in the U.S. and Europe who have done great research on EECP Therapy and presented data to ESC for consideration."

"Throughout the past decade, EECP Therapy has been offered to hundreds of thousands of patients in numerous centers and hospitals in the Unites States and abroad. During this time, we have gathered a wealth of data from many different studies, including randomized controlled trials published in peer-reviewed journals, and have received countless testimonials regarding an improvement to patients' quality of life," continued Dr. Ma. "We believe this treatment option should be made available to a wider patient base. Our responsibility is not only to support and improve this technology, but also to champion the patient who is not receiving this therapy and its benefits. Furthermore, we have a social obligation to support healthcare cost reduction through expanding role of EECP Therapy, which has been demonstrated in clinical literature to reduce re-hospitalizations and emergency room visits. We believe this high recommendation by ESC should help promote a broader acceptance of the EECP Therapy around the world."

 

 

 

http://www.vasomedical.com/vasonews_10_24_13.php

neues produkt und anstehendes pending approval from the China State FDA

 

 

hab ja eigentlich gedacht ich könnt unter 0,28$ noch zuschlagen...
vermutlich kommen am 15.11 die q-zahlen raus. mal gucken.
es sah hier weder vom chart noch der fundamentals je so gut aus.
wenns dann tatsächlich steigt soll man ja kaufen, schreibt AK.    

 

Vasomedical named on Deloitte s technology fast 500 list.

Morgen kommen die Quartalszahlen.

 

scheint wieder anzufangen sich zu bewegen.

 

Vasomedical Recorded 33% Year-over-year Growth in Revenue for the Third Quarter of 2013

14:05 14.11.13

PR Newswire

WESTBURY, N.Y., Nov. 14, 2013

WESTBURY, N.Y., Nov. 14, 2013 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO) today reported its operating results for the three months ended September 30, 2013.

"We are pleased to report that during the third quarter of 2013 the Company recorded significant growth in both the Equipment segment and the Sales Representation segment.  Total equipment sales were particularly impressive, with an increase of 97% compared to the same period last year, as we experienced a spike in sales of our EECP^® equipment in certain international markets as well as the steady sales growth from our Biox subsidiary," stated Dr. Jun Ma, President and Chief Executive Officer of Vasomedical, Inc. "The excellent performance and continued growth of Biox not only benefits the Company financially, it also provides us with a successful track record in China, paving the way for us to pursue additional acquisition and partnership opportunities there."   

"We continue to see strong results from our sales representation segment.  Given the overall strength of our team, we believe our independent sales channel model can be successfully expanded or replicated with other OEMs in different markets," concluded Dr. Ma.

Three Months Ended September 30, 2013 Financial Results

For the three months ended September 30, 2013, revenue increased 33% to $7.6 million from $5.7 million for the same period of 2012. This is attributable to a 97% increase in our equipment sales revenue to $1.4 million, as a result of a higher EECP^® sales volume and continued growth from our Biox subsidiary in China. Our Sales Representation business also had significant improvement, with commission revenue increasing 26% to $5.9 million compared to $4.7 million in the third quarter 2012.

Gross profit for the third quarter of 2013 increased 28% to $5.2 million, compared to a gross profit of $4.1 million for the third quarter of 2012. This increase is primarily a result of higher commission revenues in our Sales Representation segment arising from higher equipment delivery by GE Healthcare (GEHC) and an increase of equipment shipments from our Equipment segment.

Selling, general and administrative (SG&A) expenses for the third quarter of 2013 were $5.5 million or 72% of revenues, compared to $6.6 million, or 115% of revenues for the same period last year. The decrease in SG&A expenditures in the third quarter of 2013 resulted primarily from the completion in the second quarter of 2013 of certain non-recurring costs attributable to the renewal of the GEHC contract.

Net loss for the three months ended September 30, 2013 was $464,000, or $0.00 per basic and diluted common share, a substantial improvement compared to the net loss of $2.5 million, or $0.02 per basic and diluted common share, for the three months ended September 30, 2012. 

Net cash decreased by $2.3 million to $9.1 million at September 30, 2013 compared to net cash of $11.4 million at December 31, 2012.  The decrease is principally due to the repurchase of our common shares and payment of certain accrued liabilities.   Under the Company's share repurchase program initiated in April 2013, Vasomedical has acquired through November 8, 2013, approximately 9.3 million shares of its common stock.

Conference Call Information

The Company will host a conference call today at 1:00 p.m. ET featuring remarks by Jun Ma, Ph.D., President and CEO of Vasomedical, and Michael Beecher, Chief Financial Officer of Vasomedical. To dial into the conference call, please dial 1-866-393-1344 from the U.S. or 1-631-291-4669, internationally. All dial-in participants must use the following code to access the call: 94523097. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vasomedical's website, www.vasomedical.com, and www.kcsa.com. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call at www.vasomedical.com or www.kcsa.com. To access the dial-in replay of the call, which will be available until December 16, 2013, please dial 1-855-859-2056 or 1-404-537-3406. All dial-in participants must use the following code to access the call: 94523097.

 

ohne den Aktienrückkauf von 9,3mio Stck könnten sie einen Quartalsgewinn ausweisen.
das Risiko sinkt, der Gewinn steigt.
mal sehen wann Mr. Market das auch bemerkt.
 

...wenn die 0,3§ geknackt werden.
hier lohnt sich der nähere blick. der ceo sagt, dass sowohl das nächste quartal, als auch das komplette nächste jahr gewinnzonen versprechen.

good times ahead.  

Hab heut nochma nachkaufen können. :)

glta longs  

stabil bei geringem volumen. wenn hier noch ne news kommt, könnte schnell n neues level erreicht werden.  

da scheint sich was zu tun.  update vom 19.12.

nach letztem kenntnisstand immernoch pending approval seitens der china state FDA. laut internetseite der china fda dauert ein entsprechendes approval 6-9 monate.
zum ersten mal erwähnt wurde "mobicare" in einer NR ende oktober:

The MobiCare™ Patient Monitor that Vasomedical will introduce during the event is a multi-parameter patient monitor for bedside use and/or telemetry applications. It wirelessly transmits all patient vital signs , including ECG, respiration, SpO2, temperature and NIBP, to a bedside receiver or a tablet display, enabling patient mobility with comfort and at the same time providing ease of use to the medical staff.  Its compact and flexible

design allows for various configurations in the product line to meet specific needs of different clinical environments, such as bedside patient monitoring, supervised exercise in cardiac rehabilitation, community and home care of patients with chronic disease.  With a pending approval from the China State FDA, the MobiCare™ product line will be first introduced to the Chinese market, following which the company intends to pursue CE Mark and US FDA clearance.

 

What does "New Application: Record Initialized Not Assigned to an Examiner" mean?
The United States Patent and Trademark Office, may take about a year to fully register a trademark, during which time the trademark application goes through a series of steps, and this status informs the applicant of the first step.

Popular Misconceptions:

    "I have a Serial Number so that means I have a registered trademark!" Not exactly.  An assigned Serial Number indicates that you have initiated an application with the United States Patent and Trademark Office. All properly submitted trademark applications begin with having a "record initialized" with the USPTO. However, that doesn't necessarily mean that they will receive U.S. federal registration in the end, the USPTO is simplyacknowledging the existence of the trademark application.
       *Note* A trademark with this status, is not 'done' becoming registered with the USPTO.
       *Note* Only a "Registered" status means that you have a registered U.S. federal trademark with the USPTO.
   "Not assigned to an Examiner?? When will they start reviewing it?!" Don't worry and don't fret, the USPTO must first log the trademark application into their system before they can assign it to a trademark examiner for review. That is normally the next step.
       *Note* If you use the paper filing method, it may take 2 weeks to receive a serial number.

Is this Status update important, do I have to follow up with anything?
Yes, this status is meaningful in the sense that it informs the trademark applicant that the USPTO has received their trademark application and assigned a serial number. However, it is simply a notice to you, and does not require any follow up at the time.  

viel Gesundheit und Glück allen Mitlesern und Beteiligten im neuen Jahr.

 

http://www.legacyheartcare.com/treatment

noch reine spekulation, aber sollte diese therapie als gesundheitsvorsorge flächendeckend ermöglicht werden, rappelt es im karton.

 

...nix weiter